AAJ0 Stock Chart & Stats
€2.67
-€0.09(-3.72%)
At close: 4:00 PM EDT
€2.67
-€0.09(-3.72%)
Day’s Range― - ―
52-Week Range€1.66 - €4.92
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€220.58M
Enterprise Value€178.51M
Total Cash (Recent Filing)€236.88M
Total Debt (Recent Filing)€3.96M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 17, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding114,151,665
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.85Price Target Upside306.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.87
Revenue Forecast (FY)€257.56K
Bulls Say, Bears Say
Bulls Say
Regulatory AdvancementFast Track designation gives Perspective closer FDA interaction while advancing PSV359 in a cancer area with limited treatment options. It can help focus development planning and supports the strategic relevance of the company’s broader 212Pb radiopharmaceutical platform.
Platform And Market PositionA multi-program 212Pb pipeline combined with integrated, IP-protected infrastructure creates a potentially differentiated position across the radiopharmaceutical value chain. Regional production and direct-to-hospital delivery may support reliable fulfillment as clinical programs advance.
Low Financial LeverageVery low leverage reduces financial distress risk and preserves flexibility while Perspective funds clinical development. Growth in equity also supports the asset base, giving the company more capacity to pursue milestones without relying primarily on debt financing.
Bears Say
Limited Commercial ScaleRevenue remains extremely small and volatile relative to the company’s cost base, while persistent operating and net losses show that commercial scale has not yet been established. This weak earnings foundation limits internally generated funding and keeps execution dependent on pipeline progress.
Persistent Cash BurnHeavy and persistent cash outflows indicate that research, development, and operating needs are consuming liquidity before profitability is reached. Continued burn can require additional funding over time and may constrain the pace or scope of future clinical and manufacturing investment.
Rising Development CostsIncreasing R&D expense alongside a wider net loss raises the financial burden of advancing the pipeline before any product revenue is established. Although investment may support clinical progress, it also increases near-term funding needs and prolongs exposure to unprofitable operations.
AAJ0 FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was €1.66 and its highest was €4.92 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is €220.58M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 29 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Aug 10, 2026. The company reported -€0.19 earnings per share for the quarter, beating the consensus estimate of -€0.217 by €0.027.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.21.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 114,151,665 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -€0.19 in its last earnings report, beating expectations of -€0.217. Following the earnings report the stock price went down -1.122%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in DE:AAJ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.85 (306.28% Upside)
€10.85 (306.28% Upside)
Blogger Sentiment
Bullish
DE:AAJ0 Sentiment 86%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth €1.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.31%
12-Months-Change
Fundamentals
Return on Equity
-41.56%
Trailing 12-Months
Asset Growth
26.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Perspective Therapeutics
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
AAJ0 Stock 12 Month Forecast
Average Price Target
€10.85
▲(306.28% Upside)
Technical Analysis
Electromed
―
Quanterix
―
Viemed Healthcare
―
Nano-X Imaging
―
TriSalus Life Sciences
―











